Century Therapeutics, Inc. (IPSC)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Century Therapeutics (IPSC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago.
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.
What Makes Century Therapeutics (IPSC) a New Buy Stock
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.55 per share a year ago.
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.56 per share a year ago.
